Manufacture and characterization services(MCS) for vaccines and other biologics forinfectious diseases to 019
Ended Awarded Last action
- Contract number
- HHSN27200019
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,672,101
Award facts
- Contract value 100% obligated
- $1,672,101.05 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $28,086 | |
| Supplemental Agreement for work within scope | -$1,295 | |
| Funding Only Action | $121,535 | |
| Original award | $1,523,776 |
About this award
This is a federal contract award made by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL). The contract is for "Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases" and has a ceiling value of $1,672,101.05. It is a cost-plus-fixed-fee delivery order contract with a period of performance through July 2022.
ABL is a foreign-owned, for-profit manufacturer of goods that specializes in the development of gene therapies, vaccines, oncolytics, and immunotherapies. The contract does not have a set-aside designation. ABL has been awarded numerous federal contracts and grants, particularly from NIAID and other NIH institutes, to advance the development of medical countermeasures for various infectious diseases and other health conditions. Through this contract, ABL is providing a range of services including cGMP manufacturing, process development, analytical testing, stability studies, and project management to support NIAID's infectious disease research and product development initiatives.
Quick answers
Who was awarded contract HHSN27200019?
HHSN27200019 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 22, 2016.
How much is contract HHSN27200019 worth?
The government has obligated $1,672,101 on HHSN27200019.
Is contract HHSN27200019 an order under another contract?
Yes. HHSN27200019 is a delivery order under HHSN272201200005I, an indefinite delivery contract.
Was contract HHSN27200019 competed?
The extent of competition for HHSN27200019 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award